{
  "docId": "019de074-f95f-763f-9a80-be3b653e0df1",
  "docSlug": "502ed4e7545b260f09647399e486ae2c",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 28 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 28,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a chevron-based process flow to represent maturity stages: Proven, Under Evaluation, and Future.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-f95f-763f-9a80-be3b653e0df1/21",
  "deckHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1",
  "deckJsonHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1.json",
  "deckAnchorHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.39,
        "x": 0.57,
        "y": 0.27
      },
      "kind": "framework",
      "text": "FUTURE: Potential Therapeutic Applications (Infection, Immune RX, Inflammation, Oncology, Fibrosis, Pulmonary)",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42253256-0178-494a-941a-76435e095e22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.29,
        "y": 0.35
      },
      "kind": "framework",
      "text": "UNDER EVALUATION: Intracellular Delivery of Nucleic Acids (siRNA, ASO, mRNA, DNA)",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "542d29fb-5dbb-48ea-84a5-ed8ed7e92e97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.26,
        "x": 0.04,
        "y": 0.42
      },
      "kind": "framework",
      "text": "PROVEN: Oral Formulations of Anti-Infectives (MAT2203)",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de60d8cd-8b70-49f4-af78-5128ba1489d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Matinas is working internally and with third parties to broaden its pipeline of LNC and PS-NP-based therapeutics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af237e0d-2f31-4c66-a2e7-790b0fc5b7d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.65,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Unlocking the Full Potential of the LNC and PS-NP Platforms",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efee9383-c70a-429c-b668-fe33b0601c35",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "0a0d2d57-6668-4bdf-a30a-9ab4e8796da8",
      "evidence": "Chevron-based progression from Proven to Future",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}